Feiba NF Market Report 2026

Feiba NF Market Overview

• The Feiba NF market growth in the historic period has been driven by presence of inhibitors in hemophilia patients, limited historical treatment alternatives • Market expansion is supported by rising hemophilia diagnosis rates, expansion of home infusion programs • Growth Driver: Impact Of Rising Hemophilia Prevalence On The Growth Of The Market • Market Trend: Advancements In Routine Prophylaxis For Hemophilia Patients With Inhibitors • North America was the largest region in 2025.

What Is Covered Under Feiba NF Market?

FEIBA NF (Factor VIII Inhibitor Bypassing Activity) is a plasma-derived medication used to manage bleeding in haemophilia patients with inhibitors against factors VIII or IX. It contains coagulation factors that bypass these inhibitors, facilitating clotting. It's indicated for bleeding episodes and surgical procedures, with careful monitoring for thromboembolic risks. The main indications of feiba NF market are hemophilia A and B with inhibitors, prophylactic treatment, and on-demand treatment. Hemophilia A and B are genetic disorders where the blood doesn't clot properly, leading to excessive bleeding. Patients with inhibitors have developed antibodies that block the effectiveness of traditional clotting factor treatments. The medical indications are distributed through various channels such as hospitals, specialty pharmacies, and direct-to-consumer and are used by several end users including adult and pediatric.

What Is The Feiba NF Market Growth Forecast?

The growth in the forecast period can be attributed to rising hemophilia diagnosis rates, expansion of home infusion programs, improved inhibitor screening, growth in comprehensive hemophilia care centers, advancements in coagulation monitoring. Major trends in the forecast period include continued demand for bypassing agents, focus on bleeding control in inhibitor patients, growth in prophylactic hemophilia care, expansion of home based infusion therapy, improved safety monitoring in coagulation treatments.

Global Feiba NF Market Segmentation

1) By Indication: Hemophilia A and B with Inhibitors, Prophylactic treatment, On-Demand Treatment 2) By Distribution Channel: Hospitals, Specialty Pharmacies, Direct-To-Consumer 3) By End User: Adult, Pediatric

What Are The Drivers Of The Feiba NF Market?

The rising prevalence of hemophilia is expected to boost the growth of the feiba NF market going forward. Hemophilia refers to a rare inherited bleeding disorder characterized by the blood's inability to clot properly, leading to excessive bleeding after injuries or surgeries, as well as spontaneous internal bleeding. The rising prevalence of hemophilia is due to factors such as improved genetic testing, increased awareness and diagnosis, new mutations, and enhanced treatment options leading to longer life expectancy. FEIBA NF helps hemophilia patients by providing an effective treatment to control bleeding episodes and offer routine prophylaxis, reducing the frequency of these episodes and enhancing long-term management, ultimately improving the patient's quality of life and reducing the risks associated with hemophilia. For instance, in June 2023, according to the National Library of Medicine, a US-based biomedical library, hemophilia occurs in approximately 1 in 10,000 live births, with around 400,000 individuals worldwide affected. Hemophilia A is more common, accounting for 80-85% of cases, presenting in 1 in 5,000 live male births, while Hemophilia B presents in 1 in 30,000 live male births. Hemophilia C, caused by factor XI deficiency, is rarer, occurring in about 1 in 100,000 people, with a notable incidence among Ashkenazi Jews (around 8%). Furthermore, in June 2023, according to The World Federation of Hemophilia (WFH), a Canada-based non-profit organization, as of 2022, the estimated prevalence of hemophilia A was approximately 17.1 per 100,000 males for all cases, with 6.0 per 100,000 males for severe hemophilia A. For hemophilia B, the rates were 3.8 per 100,000 males overall and 1.1 per 100,000 males for severe cases. Therefore, the rising prevalence of hemophilia is driving the growth of the feiba NF industry. The rising healthcare expenditure is expected to propel the growth of the feiba NF market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. The rising healthcare expenditure is due to an aging population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Healthcare expenditure supports feiba NF by funding the development, approval, and accessibility of advanced treatments for hemophilia patients with inhibitors, ensuring that patients have access to life-saving therapies that control bleeding episodes and improve long-term management of their condition. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rising healthcare expenditure is driving the growth of the feiba NF industry.

Key Players In The Global Feiba NF Market

Major companies operating in the feiba nf market are Takeda Pharmaceuticals Inc.

Global Feiba NF Market Trends and Insights

The key trend in the feiba NF market is focusing on technological innovations, such as routine prophylaxis, to gain the prevention of the frequency of bleeding episodes in hemophilia patients with inhibitors. Routine prophylaxis is preventive care aimed at reducing the risk of disease or infection through measures like vaccinations, health screenings, or medications before procedures. For instance, in June 2023, Takeda Pharmaceuticals U.S.A. Inc., a US-based biopharmaceutical company, FEIBA has been approved by the Food and Drug Administration (FDA), a US-based federal agency. It is designed to control bleeding episodes but also to provide routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia patients with inhibitors. This advancement enhances its role in the long-term management of hemophilia, offering patients a more proactive approach to managing their condition. Routine prophylaxis represents a significant step forward in the treatment of hemophilia patients with inhibitors, as it helps to minimize the occurrence of bleeding episodes and improve overall quality of life.

Regional Insights

North America was the largest region in the feiba NF market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Feiba NF Market?

The feiba NF market consists of sales of FEIBA NF 500 U, 1000 U, and 2500 U, and formulations offering 350-650 U and 700-1300 U per mL designed for managing bleeding in haemophilia patients with inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Feiba NF Market Report 2026?

The feiba nf market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the feiba nf industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.